EGFR and central nervous system cancer: In LN18 glioma cells, isotopologue profiling could not reveal significant differences in 13C-enrichments (Fig. 2B) but also not in the isotopologue compositions of the selected amino acids following 213Bi-anti-EGFR-MAb treatment compared to untreated controls (Fig. 4 and Table 1).